[143] [144] [145] As of 2024 [146] federal Medicare Part D does not cover weight-loss drugs, and only a few federally-funded, state-administered Medicaid plans cover drugs for obesity
Such a move, however, could provoke enforcement actions or lawsuits from manufacturers like Lilly
This is especially appealing to individuals dealing with chronic joint discomfort, lingering injuries, or slow recovery
Gradual dose titration, as recommended in FDA labeling, remains the most evidence-based strategy for minimizing gastrointestinal adverse effects regardless of administration time
they also focus on exercise, eating well, and making sure you feel good all around